Cytosorbents (CTSO) Expected to Announce Earnings on Thursday

Key Points

• Cytosorbents (CTSO) is set to release its Q2 2025 earnings on August 7th, with analysts predicting a loss of ($0.07) per share and revenue of $9.79 million.
• The company's recent earnings report showed a negative net margin of 41.77% and a negative return on equity of 105.04%, highlighting ongoing financial challenges.
• Goldman Sachs recently increased its stake in Cytosorbents by 149.2%, signaling potential institutional interest in the company.

Cytosorbents (NASDAQ:CTSO - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $9.79 million for the quarter.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last posted its earnings results on Wednesday, May 14th. The medical research company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.02. Cytosorbents had a negative return on equity of 105.04% and a negative net margin of 41.77%. The firm had revenue of $8.73 million during the quarter, compared to analysts' expectations of $9.01 million. On average, analysts expect Cytosorbents to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cytosorbents Stock Up 2.3%

CTSO stock traded up $0.02 during midday trading on Friday, reaching $0.87. 4,609,987 shares of the company were exchanged, compared to its average volume of 64,449. The company has a market cap of $54.42 million, a price-to-earnings ratio of -3.10 and a beta of 1.19. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.30 and a current ratio of 2.61. Cytosorbents has a 1-year low of $0.71 and a 1-year high of $1.61. The stock's 50-day simple moving average is $1.04 and its 200 day simple moving average is $1.03.

Wall Street Analysts Forecast Growth

CTSO has been the subject of a number of research reports. Wall Street Zen began coverage on shares of Cytosorbents in a research report on Wednesday, May 21st. They issued a "hold" rating for the company. HC Wainwright restated a "neutral" rating and set a $1.00 price target on shares of Cytosorbents in a research note on Thursday, May 15th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $10.00 price objective on shares of Cytosorbents in a research note on Monday, July 21st.

Institutional Investors Weigh In On Cytosorbents

A hedge fund recently raised its stake in Cytosorbents stock. Goldman Sachs Group Inc. boosted its position in Cytosorbents Corporation (NASDAQ:CTSO - Free Report) by 149.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,662 shares of the medical research company's stock after purchasing an additional 37,519 shares during the period. Goldman Sachs Group Inc. owned about 0.10% of Cytosorbents worth $63,000 as of its most recent SEC filing. Institutional investors own 32.87% of the company's stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.